Business Context and Reporting Period
This Form 8-K is filed by PharmAthene, Inc. (not Altimmune, Inc.) on April 15, 2009. The report addresses a Regulation FD disclosure regarding the company's bid for a U.S. Department of Health and Human Services (DHHS) contract to supply an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory development regarding a potential government contract.
Material Changes and Developments
- RFP Amendment: On April 15, 2009, DHHS issued the fifth amendment to Request for Proposal (RFP-BARDA-08-15).
- New Requirement: Bidders must submit a comprehensive regulatory strategy plan to the U.S. Food and Drug Administration (FDA) within 15 days.
- Timeline Uncertainty: DHHS has not indicated how this new requirement will affect the final award decision timeline or the selection process.
- Bidder Status: The solicitation remains closed to new bidders.
Outlook, Risks, and Management Commentary
Management notes that there can be no assurance that DHHS will not extend the timeline further, add additional requirements, or that the Company will be awarded the contract. The filing explicitly states that the information is not "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Key Facts for Investor Verification
- Verify the company name is PharmAthene, Inc., as the input metadata referenced Altimmune, Inc.
- Confirm the deadline for submitting the FDA regulatory strategy plan (15 days from April 15, 2009).
- Monitor for further announcements regarding the contract award decision timeline.
- Assess the impact of potential delays on the company's cash burn rate, as no revenue is guaranteed from this solicitation.